LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 22.76

Change

+0.08 (+0.35)%

Market Cap

N/A

Volume

3.50K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEQT:CA iShares Core Equity Portfolio

-0.12 (-0.34%)

CAD 6.91B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.01%)

CAD 6.63B
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.01 (+0.03%)

CAD 6.19B
PHYS-U:CA Sprott Physical Gold Trust

-0.14 (-0.54%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

-0.22 (-0.58%)

CAD 4.54B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

CAD 4.20B
HXT-U:CA Global X S&P/TSX 60 Index ETF

-0.06 (-0.12%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.36 (+1.20%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

+0.35 (+2.98%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

N/A

CAD 2.78B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.79% 15% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.79% 13% F 15% F
Trailing 12 Months  
Capital Gain -11.54% 7% C- 13% F
Dividend Return 3.73% 81% B- 71% C-
Total Return -7.81% 8% B- 14% F
Trailing 5 Years  
Capital Gain -3.68% 22% F 27% F
Dividend Return 33.35% 90% A- 79% B-
Total Return 29.67% 39% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 2.07% 44% F 42% F
Dividend Return 3.12% 47% F 38% F
Total Return 1.05% 80% B- 38% F
Risk Return Profile  
Volatility (Standard Deviation) 5.96% 74% C 88% B+
Risk Adjusted Return 52.36% 58% F 62% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.